CN115197890A - 一种胰岛细胞培养基及其制备方法和用途 - Google Patents
一种胰岛细胞培养基及其制备方法和用途 Download PDFInfo
- Publication number
- CN115197890A CN115197890A CN202210623177.1A CN202210623177A CN115197890A CN 115197890 A CN115197890 A CN 115197890A CN 202210623177 A CN202210623177 A CN 202210623177A CN 115197890 A CN115197890 A CN 115197890A
- Authority
- CN
- China
- Prior art keywords
- cell culture
- culture medium
- hydrochloride
- islet cell
- islet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004153 islets of langerhan Anatomy 0.000 title claims abstract description 97
- 239000006143 cell culture medium Substances 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title abstract description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 18
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 14
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 14
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 14
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 14
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 14
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 14
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 14
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims description 14
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 13
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 13
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 13
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 10
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 claims description 10
- 229960005322 streptomycin Drugs 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 229930182555 Penicillin Natural products 0.000 claims description 8
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 8
- 229940049954 penicillin Drugs 0.000 claims description 8
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 claims description 7
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 claims description 7
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 7
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 7
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 7
- 235000019743 Choline chloride Nutrition 0.000 claims description 7
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 7
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 7
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- 239000004471 Glycine Substances 0.000 claims description 7
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 7
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 claims description 7
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 7
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 7
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 7
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 7
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 7
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 7
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 7
- 239000004395 L-leucine Substances 0.000 claims description 7
- 235000019454 L-leucine Nutrition 0.000 claims description 7
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 7
- 229930195722 L-methionine Natural products 0.000 claims description 7
- 229930182821 L-proline Natural products 0.000 claims description 7
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 7
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 claims description 7
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 claims description 7
- 229960003767 alanine Drugs 0.000 claims description 7
- 229960005261 aspartic acid Drugs 0.000 claims description 7
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 7
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 7
- 239000001110 calcium chloride Substances 0.000 claims description 7
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 7
- 229960003178 choline chloride Drugs 0.000 claims description 7
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 7
- 229910000365 copper sulfate Inorganic materials 0.000 claims description 7
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims description 7
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 7
- 239000011790 ferrous sulphate Substances 0.000 claims description 7
- 235000003891 ferrous sulphate Nutrition 0.000 claims description 7
- 229960000304 folic acid Drugs 0.000 claims description 7
- 235000019152 folic acid Nutrition 0.000 claims description 7
- 239000011724 folic acid Substances 0.000 claims description 7
- 229960000367 inositol Drugs 0.000 claims description 7
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 7
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 7
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 7
- 229960003136 leucine Drugs 0.000 claims description 7
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims description 7
- 235000019136 lipoic acid Nutrition 0.000 claims description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 7
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 7
- 229960004452 methionine Drugs 0.000 claims description 7
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 7
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 7
- 229960003531 phenolsulfonphthalein Drugs 0.000 claims description 7
- 239000001103 potassium chloride Substances 0.000 claims description 7
- 235000011164 potassium chloride Nutrition 0.000 claims description 7
- 229960002429 proline Drugs 0.000 claims description 7
- 229960002477 riboflavin Drugs 0.000 claims description 7
- 235000019192 riboflavin Nutrition 0.000 claims description 7
- 239000002151 riboflavin Substances 0.000 claims description 7
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 7
- 229960001153 serine Drugs 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 7
- 229960000344 thiamine hydrochloride Drugs 0.000 claims description 7
- 235000019190 thiamine hydrochloride Nutrition 0.000 claims description 7
- 239000011747 thiamine hydrochloride Substances 0.000 claims description 7
- 229960002663 thioctic acid Drugs 0.000 claims description 7
- 229940104230 thymidine Drugs 0.000 claims description 7
- 229960004295 valine Drugs 0.000 claims description 7
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 7
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 7
- 229960001763 zinc sulfate Drugs 0.000 claims description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- 229930182816 L-glutamine Natural products 0.000 claims description 6
- 229930182844 L-isoleucine Natural products 0.000 claims description 6
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims description 6
- 239000004473 Threonine Substances 0.000 claims description 6
- 229930003756 Vitamin B7 Natural products 0.000 claims description 6
- 229960001230 asparagine Drugs 0.000 claims description 6
- 229960000310 isoleucine Drugs 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 6
- 229960002898 threonine Drugs 0.000 claims description 6
- 229960004441 tyrosine Drugs 0.000 claims description 6
- 235000011912 vitamin B7 Nutrition 0.000 claims description 6
- 239000011735 vitamin B7 Substances 0.000 claims description 6
- 229930003779 Vitamin B12 Natural products 0.000 claims description 5
- 230000003204 osmotic effect Effects 0.000 claims description 5
- 235000008160 pyridoxine Nutrition 0.000 claims description 5
- 239000011677 pyridoxine Substances 0.000 claims description 5
- 229940054269 sodium pyruvate Drugs 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 235000019163 vitamin B12 Nutrition 0.000 claims description 5
- 239000011715 vitamin B12 Substances 0.000 claims description 5
- 229940011671 vitamin b6 Drugs 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims 6
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 claims 3
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 claims 3
- 229930003270 Vitamin B Natural products 0.000 claims 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims 2
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims 2
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims 2
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims 2
- 235000019156 vitamin B Nutrition 0.000 claims 2
- 239000011720 vitamin B Substances 0.000 claims 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims 1
- 239000012467 final product Substances 0.000 claims 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims 1
- 238000000338 in vitro Methods 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 7
- 238000004113 cell culture Methods 0.000 abstract description 5
- 239000002609 medium Substances 0.000 description 21
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 8
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 8
- 229960003966 nicotinamide Drugs 0.000 description 8
- 235000005152 nicotinamide Nutrition 0.000 description 8
- 239000011570 nicotinamide Substances 0.000 description 8
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 4
- 229960005190 phenylalanine Drugs 0.000 description 4
- 229960004799 tryptophan Drugs 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- DAQHMCWYXJEOCG-UHFFFAOYSA-N 2-oxopropanoic acid;sodium Chemical compound [Na].CC(=O)C(O)=O DAQHMCWYXJEOCG-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 150000008545 L-lysines Chemical class 0.000 description 1
- GKHOLUJNLGYFHA-UHFFFAOYSA-N [Na].CC(C)=O Chemical compound [Na].CC(C)=O GKHOLUJNLGYFHA-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明提供了一种胰岛细胞培养基及其制备方法和用途,属于细胞培养技术领域。本发明胰岛细胞培养基可将胰岛细胞体外培养时间延长至30天以上,且仍然能够保持胰岛细胞的活性,对胰岛细胞培养具有重要意义。
Description
技术领域
本发明属于细胞培养技术领域,具体涉及一种胰岛细胞培养基及其制备方法和用途。
背景技术
胰岛细胞是人体内重要的一种细胞,调节人体中血糖含量。胰岛细胞与糖尿病有关,对胰岛细胞进行研究或者利用胰岛细胞对药物进行筛选评价,对于糖尿病的治疗有重要意义。
但是胰岛细胞不能冻存,且体外不能长时间存活,因此限制了体外对胰岛细胞的研究。CMRL 1066培养基为培养胰岛细胞常用的培养基,但其在体外培养胰岛细胞的时间很短。目前。缺少可以延长胰岛细胞体外培养时间,使胰岛细胞在体外保持良好活性的胰岛细胞培养基。如果能够研究一种胰岛细胞培养基,延长胰岛细胞体外培养时间,保持胰岛细胞的体外活性,这将有利于对胰岛细胞的研究。
发明内容
本发明的目的是提供一种胰岛细胞培养基及其制备方法和用途。
本发明提供了一种胰岛细胞培养基,每1L胰岛细胞培养基由如下组分组成:氯化钙30~35mg、硫酸铜0.001~0.1mg、磷酸二氢钾80~90mg、磷酸氢二钠150~160mg、硫酸亚铁0.1~1mg、氯化钾280~290mg、硫酸镁70~80mg、氯化钠7~9g、硫酸锌0.01~0.1mg、L-精氨酸盐酸盐210~220mg、L-谷氨酰胺140~150mg、甘氨酸1~10mg、L-组氨酸盐酸盐20~30mg、L-异亮氨酸1~10mg、L-亮氨酸10~20mg、L-赖氨酸盐酸盐20~30mg、L-蛋氨酸1~10mg、L-苯丙氨酸1~10mg、L-丝氨酸10~20mg、L-苏氨酸1~10mg、L-丙氨酸1~10mg、L-天门冬酰胺10~20mg、L-天门冬氨酸10~20mg、L-半胱氨酸盐酸盐30~40mg、L-脯氨酸10~20mg、L-色氨酸0.1~1mg、L-酪氨酸1~10mg、L-缬氨酸1~10mg、D-葡萄糖1~2g、次黄嘌呤1~10mg、硫辛酸0.1~1mg、酚红1~10mg、胸苷0.1~1mg、丙酮酸钠100~110mg、维生素H0.01~0.1mg、D-泛酸钙0.1~1mg、氯化胆碱0.1~1mg、叶酸1~10mg、肌醇0.1~1mg、烟酰胺0.1~1mg、酸吡哆醇0.1~1mg、核黄素0.1~1mg、盐酸硫胺1~10mg、维生素B12 1~10mg、HBS 2~3g、IBMX 10~20mg、尼克酰胺1~2g、青霉素0.1~1g、链霉素0.1~1g,余量为水。
进一步地,每1L胰岛细胞培养基由如下组分组成:氯化钙33~34mg、硫酸铜0.001~0.002mg、磷酸二氢钾82~83mg、磷酸氢二钠153~154mg、硫酸亚铁0.4~0.5mg、氯化钾285~286mg、硫酸镁74~75mg、氯化钠7.4~7.5g、硫酸锌0.01~0.02mg、L-精氨酸盐酸盐210~211mg、L-谷氨酰胺145~146mg、甘氨酸7~8mg、L-组氨酸盐酸盐22~23mg、L-异亮氨酸2~3mg、L-亮氨酸12~13mg、L-赖氨酸盐酸盐29~30mg、L-蛋氨酸4~5mg、L-苯丙氨酸5~6mg、L-丝氨酸10~11mg、L-苏氨酸3~4mg、L-丙氨酸9~10mg、L-天门冬酰胺15~16mg、L-天门冬氨酸12~13mg、L-半胱氨酸盐酸盐36~37mg、L-脯氨酸11~12mg、L-色氨酸0.5~0.6mg、L-酪氨酸1~2mg、L-缬氨酸3~4mg、D-葡萄糖1.1~1.2g、次黄嘌呤4~5mg、硫辛酸0.1~0.2mg、酚红1~2mg、胸苷0.6~0.7mg、丙酮酸钠109~110mg、维生素H 0.02~0.03mg、D-泛酸钙0.7~0.8mg、氯化胆碱0.6~0.7mg、叶酸1~2mg、肌醇0.5~0.6mg、烟酰胺0.6~0.7mg、酸吡哆醇0.2~0.3mg、核黄素0.3~0.4mg、盐酸硫胺1~2mg、维生素B12 1~2mg、HBS2.4~2.5g、IBMX 11~12mg、尼克酰胺1.2~1.3g、青霉素0.1~0.2g、链霉素0.1~0.2g,余量为水。
进一步地,每1L胰岛细胞培养基由如下组分组成:氯化钙33.29mg、硫酸铜0.0016mg、磷酸二氢钾83mg、磷酸氢二钠153.7mg、硫酸亚铁0.45mg、氯化钾285mg、硫酸镁74.62mg、氯化钠7.4g、硫酸锌0.016mg、L-精氨酸盐酸盐211mg、L-谷氨酰胺146mg、甘氨酸7.41mg、L-组氨酸盐酸盐23mg、L-异亮氨酸2.6mg、L-亮氨酸13mg、L-赖氨酸盐酸盐29mg、L-蛋氨酸4.48mg、L-苯丙氨酸5mg、L-丝氨酸10.5mg、L-苏氨酸3.57mg、L-丙氨酸9mg、L-天门冬酰胺15.01mg、L-天门冬氨酸13mg、L-半胱氨酸盐酸盐36.24mg、L-脯氨酸11.5mg、L-色氨酸0.6mg、L-酪氨酸1.8mg、L-缬氨酸3.5mg、D-葡萄糖1.1g、次黄嘌呤4mg、硫辛酸0.2mg、酚红1.2mg、胸苷0.7mg、丙酮酸钠110mg、维生素H 0.024mg、D-泛酸钙0.715mg、氯化胆碱0.698mg、叶酸1.32mg、肌醇0.541mg、烟酰胺0.615mg、酸吡哆醇0.206mg、核黄素0.376mg、盐酸硫胺1mg、维生素B12 1.36mg、HBS 2.5g、IBMX 11.12mg、尼克酰胺1.22g、青霉素0.1g、链霉素0.1g,余量为水。
进一步地,所述胰岛细胞培养基的pH值为7.2-7.4。
进一步地,所述胰岛细胞培养基的渗透压为260-300mmol/L。
本发明还提供了一种制备前述的胰岛细胞培养基的方法,它包括如下步骤:
1)将各组分溶解于水中;
2)灭菌,即得。
进一步地,步骤2)中,所述灭菌为使用0.22μm过滤器过滤灭菌。
本发明还提供了前述的胰岛细胞培养基在培养胰岛细胞中的用途。
胰岛分离提取胰岛细胞时因分离不纯存在一些杂细胞,通过长期培养可以去除这些杂细胞,提高胰岛细胞的纯度。但是,胰岛细胞很难在体外长时间培养,利用现有培养基在体外培养胰岛细胞一般只能培养7天左右。因此寻找新的培养基,延长胰岛细胞在体外培养的时间十分必要。
本发明胰岛细胞培养基可将胰岛细胞体外培养时间延长至30天以上,且仍然能够保持胰岛细胞的活性,对胰岛细胞培养具有重要意义。
显然,根据本发明的上述内容,按照本领域的普通技术知识和惯用手段,在不脱离本发明上述基本技术思想前提下,还可以做出其它多种形式的修改、替换或变更。
以下通过实施例形式的具体实施方式,对本发明的上述内容再作进一步的详细说明。但不应将此理解为本发明上述主题的范围仅限于以下的实例。凡基于本发明上述内容所实现的技术均属于本发明的范围。
附图说明
图1为本发明胰岛细胞培养基培养胰岛细胞1d、5d、10d、15d、20d、25d和30d的细胞形貌。
图2为对照组1培养基培养胰岛细胞0d、2d、3d、4d、6d、10d和15d的细胞形貌。
图3为对照组2培养基培养胰岛细胞0d、2d、3d、4d的细胞形貌。
具体实施方式
本发明具体实施方式中使用的原料、设备均为已知产品,通过购买市售产品获得。
实施例1、本发明胰岛细胞培养基
本发明胰岛细胞培养基的配方如表1所示。
表1.本发明猪胰岛细胞培养基的配方
双抗(Ps)为青霉素和链霉素的混合水溶液;其中,每100mL双抗中含青霉素和链霉素各1g。
测定本发明胰岛细胞培养基的pH值和渗透压,如果pH值不在7.2-7.4范围,可用1NNaOH或1N HCl调节胰岛细胞培养基的pH值至7.2-7.4,如果渗透压不在260-300mmol/L范围,需重新配置胰岛细胞培养液。使用0.22μm过滤器过滤灭菌上述胰岛细胞培养基。
如果组分的分子量与表1中不一致,可根据最终的原料浓度重新计算所需要的剂量。经过计算,每1L本发明胰岛细胞培养基中各原料组分的用量如下:氯化钙33.29mg、硫酸铜0.0016mg、磷酸二氢钾83mg、磷酸氢二钠153.7mg、硫酸亚铁0.45mg、氯化钾285mg、硫酸镁74.62mg、氯化钠7.4g、硫酸锌0.016mg、L-精氨酸盐酸盐211mg、L-谷氨酰胺146mg、甘氨酸7.41mg、L-组氨酸盐酸盐23mg、L-异亮氨酸2.6mg、L-亮氨酸13mg、L-赖氨酸盐酸盐29mg、L-蛋氨酸4.48mg、L-苯丙氨酸5mg、L-丝氨酸10.5mg、L-苏氨酸3.57mg、L-丙氨酸9mg、L-天门冬酰胺15.01mg、L-天门冬氨酸13mg、L-半胱氨酸盐酸盐36.24mg、L-脯氨酸11.5mg、L-色氨酸0.6mg、L-酪氨酸1.8mg、L-缬氨酸3.5mg、D-葡萄糖1.1g、次黄嘌呤4mg、硫辛酸0.2mg、酚红1.2mg、胸苷0.7mg、丙酮酸钠110mg、维生素H 0.024mg、D-泛酸钙0.715mg、氯化胆碱0.698mg、叶酸1.32mg、肌醇0.541mg、烟酰胺0.615mg、酸吡哆醇0.206mg、核黄素0.376mg、盐酸硫胺1mg、维生素B12 1.36mg、HBS 2.5g、IBMX 11.12mg、尼克酰胺1.22g、青霉素100mg、链霉素100mg,余量为水。
以下通过具体试验例证明本发明的有益效果。
试验例1、本发明胰岛细胞培养基对胰岛细胞的培养
1、实验方法
实施例1制备的胰岛细胞培养基为实验组,并设置对照组1和对照组2。
对照组1:采用实施例1表1中的组分配方制备培养基,只是将IBMX的用量由11.12mg改为5.56mg。培养基的pH值为7.2-7.4,渗透压为260-300mmol/L。
对照组2:采用市售的CMRL 1066培养基,CMRL 1066培养基为目前培养胰岛细胞常用的培养基。
分别采用上述三种培养基培养胰岛细胞,具体方法如下:
按照本领域常规手段分离一头成年猪的胰岛细胞,猪的编号为210,分离后将此批次细胞分为3份,分别使用实验组、对照组1和对照组2培养基培养细胞至T175细胞培养瓶中,放置于二氧化碳培养箱,37.5摄氏度,5%二氧化碳进行胰岛细胞培养。培养不同时间后,观察胰岛细胞状态:经培养后胰岛细胞聚团生长,说明胰岛细胞状态好;经培养后胰岛细胞不聚团生长,且分散凋零,说明胰岛细胞状态不好。同时在培养的最后一天对各组胰岛细胞进行活死细胞染色,绿色荧光代表活细胞,红色荧光代表死细胞。
2、实验结果
使用实验组培养基培养胰岛细胞1d、5d、10d、15d、20d、25d和30d的细胞形貌如图1所示。由图1可知使用本发明培养基培养胰岛细胞,培养30天后胰岛细胞仍然能够聚团生长,保持良好的状态,通过活死细胞染色可知死细胞数量很少,细胞活性良好。证明使用本发明培养基,胰岛细胞体外培养时间可延长至30天以上。
使用对照组1培养基培养胰岛细胞0d、2d、3d、4d、6d、10d和15d的细胞形貌如图2所示。由图2可知使用对照组1培养基培养胰岛细胞,在体外培养15d后胰岛细胞分散凋零,状态不好,通过活死细胞染色可知细胞大量凋亡,活性变差。说明使用对照组1培养基培养胰岛细胞,培养时间不超过15天。
使用对照组2培养基培养胰岛细胞0d、2d、3d、4d的细胞形貌如图3所示。由图3可知使用对照组2培养基培养胰岛细胞后,胰岛细胞在体外培养4d时已基本凋亡,没有活细胞存在。
由上述结果可知:与其他胰岛细胞培养基相比,本发明制备的胰岛细胞培养液可以有效延长胰岛细胞在体外的培养时间,保持细胞活性。
综上,本发明胰岛细胞培养基可将胰岛细胞体外培养时间延长至30天以上,且仍然能够保持胰岛细胞的活性,对胰岛细胞培养具有重要意义。
Claims (8)
1.一种胰岛细胞培养基,其特征在于:每1L胰岛细胞培养基由如下组分组成:氯化钙30~35mg、硫酸铜0.001~0.1mg、磷酸二氢钾80~90mg、磷酸氢二钠150~160mg、硫酸亚铁0.1~1mg、氯化钾280~290mg、硫酸镁70~80mg、氯化钠7~9g、硫酸锌0.01~0.1mg、L-精氨酸盐酸盐210~220mg、L-谷氨酰胺140~150mg、甘氨酸1~10mg、L-组氨酸盐酸盐20~30mg、L-异亮氨酸1~10mg、L-亮氨酸10~20mg、L-赖氨酸盐酸盐20~30mg、L-蛋氨酸1~10mg、L-苯丙氨酸1~10mg、L-丝氨酸10~20mg、L-苏氨酸1~10mg、L-丙氨酸1~10mg、L-天门冬酰胺10~20mg、L-天门冬氨酸10~20mg、L-半胱氨酸盐酸盐30~40mg、L-脯氨酸10~20mg、L-色氨酸0.1~1mg、L-酪氨酸1~10mg、L-缬氨酸1~10mg、D-葡萄糖1~2g、次黄嘌呤1~10mg、硫辛酸0.1~1mg、酚红1~10mg、胸苷0.1~1mg、丙酮酸钠100~110mg、维生素H 0.01~0.1mg、D-泛酸钙0.1~1mg、氯化胆碱0.1~1mg、叶酸1~10mg、肌醇0.1~1mg、烟酰胺0.1~1mg、酸吡哆醇0.1~1mg、核黄素0.1~1mg、盐酸硫胺1~10mg、维生素B12 1~10mg、HBS 2~3g、IBMX10~20mg、尼克酰胺1~2g、青霉素0.1~1g、链霉素0.1~1g,余量为水。
2.根据权利要求1所述的胰岛细胞培养基,其特征在于:每1L胰岛细胞培养基由如下组分组成:氯化钙33~34mg、硫酸铜0.001~0.002mg、磷酸二氢钾82~83mg、磷酸氢二钠153~154mg、硫酸亚铁0.4~0.5mg、氯化钾285~286mg、硫酸镁74~75mg、氯化钠7.4~7.5g、硫酸锌0.01~0.02mg、L-精氨酸盐酸盐210~211mg、L-谷氨酰胺145~146mg、甘氨酸7~8mg、L-组氨酸盐酸盐22~23mg、L-异亮氨酸2~3mg、L-亮氨酸12~13mg、L-赖氨酸盐酸盐29~30mg、L-蛋氨酸4~5mg、L-苯丙氨酸5~6mg、L-丝氨酸10~11mg、L-苏氨酸3~4mg、L-丙氨酸9~10mg、L-天门冬酰胺15~16mg、L-天门冬氨酸12~13mg、L-半胱氨酸盐酸盐36~37mg、L-脯氨酸11~12mg、L-色氨酸0.5~0.6mg、L-酪氨酸1~2mg、L-缬氨酸3~4mg、D-葡萄糖1.1~1.2g、次黄嘌呤4~5mg、硫辛酸0.1~0.2mg、酚红1~2mg、胸苷0.6~0.7mg、丙酮酸钠109~110mg、维生素H 0.02~0.03mg、D-泛酸钙0.7~0.8mg、氯化胆碱0.6~0.7mg、叶酸1~2mg、肌醇0.5~0.6mg、烟酰胺0.6~0.7mg、酸吡哆醇0.2~0.3mg、核黄素0.3~0.4mg、盐酸硫胺1~2mg、维生素B12 1~2mg、HBS 2.4~2.5g、IBMX 11~12mg、尼克酰胺1.2~1.3g、青霉素0.1~0.2g、链霉素0.1~0.2g,余量为水。
3.根据权利要求2所述的胰岛细胞培养基,其特征在于:每1L胰岛细胞培养基由如下组分组成:氯化钙33.29mg、硫酸铜0.0016mg、磷酸二氢钾83mg、磷酸氢二钠153.7mg、硫酸亚铁0.45mg、氯化钾285mg、硫酸镁74.62mg、氯化钠7.4g、硫酸锌0.016mg、L-精氨酸盐酸盐211mg、L-谷氨酰胺146mg、甘氨酸7.41mg、L-组氨酸盐酸盐23mg、L-异亮氨酸2.6mg、L-亮氨酸13mg、L-赖氨酸盐酸盐29mg、L-蛋氨酸4.48mg、L-苯丙氨酸5mg、L-丝氨酸10.5mg、L-苏氨酸3.57mg、L-丙氨酸9mg、L-天门冬酰胺15.01mg、L-天门冬氨酸13mg、L-半胱氨酸盐酸盐36.24mg、L-脯氨酸11.5mg、L-色氨酸0.6mg、L-酪氨酸1.8mg、L-缬氨酸3.5mg、D-葡萄糖1.1g、次黄嘌呤4mg、硫辛酸0.2mg、酚红1.2mg、胸苷0.7mg、丙酮酸钠110mg、维生素H0.024mg、D-泛酸钙0.715mg、氯化胆碱0.698mg、叶酸1.32mg、肌醇0.541mg、烟酰胺0.615mg、酸吡哆醇0.206mg、核黄素0.376mg、盐酸硫胺1mg、维生素B12 1.36mg、HBS 2.5g、IBMX11.12mg、尼克酰胺1.22g、青霉素0.1g、链霉素0.1g,余量为水。
4.根据权利要求1~3任一项所述的胰岛细胞培养基,其特征在于:所述胰岛细胞培养基的pH值为7.2-7.4。
5.根据权利要求1~3任一项所述的胰岛细胞培养基,其特征在于:所述胰岛细胞培养基的渗透压为260-300mmol/L。
6.一种制备权利要求1~5任一项所述的胰岛细胞培养基的方法,其特征在于:它包括如下步骤:
1)将各组分溶解于水中;
2)灭菌,即得。
7.根据权利要求6所述的方法,其特征在于:步骤2)中,所述灭菌为使用0.22μm过滤器过滤灭菌。
8.权利要求1~5任一项所述的胰岛细胞培养基在培养胰岛细胞中的用途。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210623177.1A CN115197890A (zh) | 2022-06-02 | 2022-06-02 | 一种胰岛细胞培养基及其制备方法和用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210623177.1A CN115197890A (zh) | 2022-06-02 | 2022-06-02 | 一种胰岛细胞培养基及其制备方法和用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115197890A true CN115197890A (zh) | 2022-10-18 |
Family
ID=83575727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210623177.1A Pending CN115197890A (zh) | 2022-06-02 | 2022-06-02 | 一种胰岛细胞培养基及其制备方法和用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115197890A (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997039107A2 (en) * | 1996-04-12 | 1997-10-23 | The Governors Of The University Of Alberta | Methods for increasing the maturation of cells |
| CN101033460A (zh) * | 2007-01-19 | 2007-09-12 | 牛申 | 新生猪胰岛细胞分离、纯化和培养方法 |
| CN112251397A (zh) * | 2020-10-30 | 2021-01-22 | 湖南赛诺生物科技股份有限公司 | 一种新生猪胰岛细胞培养方法 |
-
2022
- 2022-06-02 CN CN202210623177.1A patent/CN115197890A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997039107A2 (en) * | 1996-04-12 | 1997-10-23 | The Governors Of The University Of Alberta | Methods for increasing the maturation of cells |
| CN101033460A (zh) * | 2007-01-19 | 2007-09-12 | 牛申 | 新生猪胰岛细胞分离、纯化和培养方法 |
| CN112251397A (zh) * | 2020-10-30 | 2021-01-22 | 湖南赛诺生物科技股份有限公司 | 一种新生猪胰岛细胞培养方法 |
Non-Patent Citations (2)
| Title |
|---|
| MOURAD等: "Long-term culture and in vitro maturation of macroencapsulated adult and neonatal porcine islets", 《XENOTRANSPLANTATION》, vol. 26, pages 2 * |
| 王永芬等: "《动物细胞培养技术》", 华中科技大学出版社, pages: 245 - 249 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105018416B (zh) | 一种悬浮培养bhk-21细胞的无血清无动物源培养基及其配制方法 | |
| CN107460159B (zh) | 无血清、无蛋白补料培养基及其制备方法和运用 | |
| CN104450614B (zh) | 一种无动物蛋白源的免疫细胞无血清培养基及其使用方法 | |
| Nowak et al. | Improved culture conditions stimulate gluconeogenesis in primary cultures of renal proximal tubule cells | |
| CN101760442B (zh) | 适于mdck细胞大规模贴壁培养和单细胞悬浮培养的无血清培养基 | |
| CN106834229B (zh) | 用于人免疫杀伤细胞体外扩增的无血清培养基 | |
| CN111304149B (zh) | 一种支持hek293细胞悬浮培养的无血清无蛋白培养基及其制备方法和应用 | |
| CN110934132A (zh) | 一种无血清无dmso细胞冻存液及其制备方法 | |
| WO2018164228A1 (ja) | Ror1陽性の間葉系幹細胞を含有する、線維症を伴う疾患の予防又は処置のための医薬組成物、及びその調製方法、並びにror1陽性の間葉系幹細胞を用いる線維症を伴う疾患の予防又は処置方法 | |
| CN114606200B (zh) | Sp2/0细胞培养基及生产重组犬细小病毒单克隆抗体的方法 | |
| CN111019883B (zh) | Cho细胞悬浮培养的无血清无蛋白培养基及其用途 | |
| CN110982776B (zh) | 肝细胞的体外扩增培养方法及应用 | |
| Wu et al. | Host-microbiota interaction in intestinal stem cell homeostasis | |
| CN106399224B (zh) | 无血清无蛋白细胞培养基 | |
| CN110592000A (zh) | 一种支持bhk细胞高密度悬浮培养的无血清培养基 | |
| CN116790477A (zh) | 一种支持cho细胞高密度培养的无血清培养基及其制备方法与应用 | |
| CN104152412A (zh) | 一种适用于临床的高效扩增nk细胞的培养体系 | |
| CN115197890A (zh) | 一种胰岛细胞培养基及其制备方法和用途 | |
| CN104152413A (zh) | 一种适用于临床的高效扩增nk细胞的培养体系的应用 | |
| CN112458052A (zh) | 一种免疫细胞培养基 | |
| CN115786254A (zh) | 一种促进体外培养细胞生成外泌体的培养基及其诱导方法 | |
| CN103421736A (zh) | Cho细胞培养中替代动物血清的培养基添加剂及其配制方法 | |
| CN105602898A (zh) | 一种能高效扩增人淋巴细胞的无动物源性培养基 | |
| EP2543369A2 (en) | Solution for peritoneal dialysis | |
| CN110117573A (zh) | 一种无血清细胞培养基及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20221018 |
|
| RJ01 | Rejection of invention patent application after publication |